Literature DB >> 33748953

Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.

Ayumi Kuzume1, Rikako Tabata1, Toshiki Terao1, Takafumi Tsushima1, Daisuke Miura1, Kentaro Narita1, Masami Takeuchi1, Kosei Matsue1.   

Abstract

Entities:  

Year:  2021        PMID： 33748953     DOI： 10.1111/bjh.17412

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.

Authors:  Catarina Geraldes; Manuel Neves; Sérgio Chacim; Fernando Leal da Costa
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

2.  Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second.

Authors:  Jin-Hyo Kim; Sung-Soo Park; Jae-Ho Yoon; Sung-Eun Lee; Hee-Je Kim; Chang-Ki Min
Journal:  Blood Res       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.